Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2331-2334

  Lumachi, Franco ^a   Basso, Stefano M M ^b   Bonamini, Manuela ^b   Marzano, Bernardo ^b   Milan, Elisa ^b   Waclaw, Beata U ^b   Chiara, Giordano B ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Breast cancer; CA 15 3; CEA; Elderly; Postmenopausal; Relapse; Tumour markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL;

EID: 77955072830     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Cheung KL, Graves CRL and Robertson JFR: Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26: 91-102, 2000.
3. Lumachi F, Ermani M, Brandes AA, Basso SM, Basso U and Boccagni P: Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res 21: 4105-4108, 2001.
4. Lumachi F and Basso SMM: Serum tumor markers in patients with breast cancer. Exp Rev Anticancer Ther 4: 921-931, 2004. (Pubitemid 39359875)
5. Martin A, Corte MD, Alvarez AM, Rodriguez JC, Andicoechea A, Bongera M, Junquera S, Pidal D, Allende MT, Muñiz JL and Vizoso F: Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 26: 3965-3972, 2006.
6. Lumachi F, Basso SMM, Brandes AA, Pagano D and Ermani M: Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 24: 3221-3224, 2004. (Pubitemid 39390976)
7. American Joint Committee on Cancer: Breast. In: AJCC Cancer Staging Handbook, 6th edition. New York: Springer-Verlag, pp. 257-281, 2002.
8. Tabàr L, Duffy SW, Vitak B, Chen H and Prevost TC: The natural history of breast carcinoma: what have we learned from screening? Cancer 86: 449-462, 1999.
9. Zheng B: Breast cancer: computer-aided detection. In: Hayat MA (ed.). Methods of Cancer Diagnosis, Therapy, and Prognosis. Heidelberg: Springer, pp. 5-27, 2008.
10. Ravaioli A, Bagli L, Zucchini A and Monti F: Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif 31: 113-126, 1998.
11. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altojai G, Locker GJ, Mader R, Zielinski CC and Steger GG: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 6: 81-87, 2006.
12. Lumachi F and Basso SMM: Serum tumor markers in breast cancer. In: Swenson LI (ed.). Progress in Tumor Marker Research. New York, NY: Nova Biomedical Books, pp. 83-100, 2007.
13. Chourin S, Georgescu D, Gray C, Guillemet C, Loeb A, Veyret C and Basuyau JP: Value of CA 15-3 determination in the initial management of breast cancer patients. Ann Oncol 20: 962-964, 2009.
14. Cheung KL, Graves CRL and Robertson JFR: Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26: 91-102, 2000.
15. Keshaviah AS, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thurlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber R, Coates AS and Goldhirsch A: CA 15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 18: 701-708, 2007.
16. Laessing D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeinf I and Stieber P: Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27: 1963-1968, 2007.
17. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR and Davidson NE: American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24: 5091-5097, 2006.
18. Park B-W, Oh J-W, Kim J-M-, Park SH, Kim K-S, Kim JH and Lee KS: Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19: 675-681, 2008.
19. Mariani L, Miceli R, Michilin S and Gion M: Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumor recurrences. Biomarkers 14: 130-136, 2009.